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Abstract 
Dendritic cells (DCs) have shown promise for use in cancer vaccine and cancer 
immunotherapy studies. However, we demonstrate that cancer cell lines can negatively 
interfere with DC generation in GM-CSF derived cultures, although cancer cells are able 
to enhance CD80 cell surface activation marker and cytokine secretion. Furthermore, in 
the presence of cancer cells, GM-CSF derived DCs are unable to stimulate T cells. 
Additional stimulation with LPS can not fully reverse the suppressive effect of cancer cells 
or supernatant. Hence, it is imperative to understand the immunosuppressive effects of 
cancer on DCs in order for DC-based cancer immunotherapy to be successful. 
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Introduction 
Cancer cells, being genetically less stable than normal cells, mutate and transform under 
the constant surveillance of the immune system. Through this selection pressure, they 
modify the expressions or alter the expression levels of normal proteins, which render 
them capable of evading apoptosis and express immunosuppressive cytokines [1, 2]. This 
allows them to resist being removed, prevent stem cells from differentiating into mature 
dendritic cells (DCs) and suppress Th1 immune response [3]. 
Over the last decade, many studies have attempted to establish the critical role of 
DCs in the maintenance of immunologic integrity, and given their unique characteristics, 
they have been promising targets for developing new cancer immunotherapies. However, 
the strongly immunosuppressive nature of tumour cells prevents an effective immune 
response from being activated. To date, both human and murine cancer immunological 
studies have used various sources of cancer antigens, such as, whole tumour cells, dead 
tumour cells, cancer-associated proteins/peptides and DNA, and have achieved limited 
protection against tumours [4, 5]. Unfortunately, these results only extended patients’ 
lifespan by a few months at best [6]. Recent cancer immunotherapeutic studies have also 
concentrated on eradicating cancer immunosuppression on T-cell activation. These 
studies focused on the blockade of the T-cell inhibitory receptors cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) and programmed death-1 (PD-1) and its ligand, PD-L1 [7-
12]. While these studies have shown an improvement in patients’ overall response rate 
and overall survival, they only extended patients’ lifespan by close to a year. 
Retrospectively, the ideal focus of cancer immunotherapies is probably to generate DCs 
that are stable upon activation and able to initiate lasting interaction with T-cells to 
eliminate the tumour cells, and then use them in conjunction with anti-CTLA-4 and/or anti-
PD-1 therapy to boost T-cell response.  
DCs express co-stimulatory markers such as CD80 and CD86 which are important 
in mediating T-cell functions [13-16]. Engagement of CD28 on T-cell by CD80 and CD86 
induces T-cell activation, proliferation and secretion of immunostimulatory cytokines such 
as IL-1, IL-6 and IL-12 [17]. However, studies have also shown that CD80 and CD86 can 
bind to CTLA-4, which induces T-cell inhibition through the production of indoleamine 2,3-
dioxygenase [4, 18].  
We have shown that the early GM-CSF derived DCs are fully functional in terms of 
endocytosis, up-regulating activation markers upon TLR stimulation [14, 16]. They are 
comparable, if not better, to the GM-CSF + IL-4 equivalents. These early GM-CSF-
derived DCs express lower levels of activation markers than early GM-CSF + IL-4-derived 
DCs, however as we demonstrate herein, these early DCs derived from GM-CSF cultures 
rapidly increased the expression levels of CD80, CD86 and MHCII upon LPS and CpG 
stimulation [14, 16], and are capable of secreting cytokines and chemokines after 
stimulation. In addition, these early GM-CSF-derived DCs, like the early GM-CSF + IL-4-
derived DCs, can stimulate T-cell proliferation after exposure to LPS. Using these early 
GM-CSF-derived DCs, we determined the effects of cancer cells (with the use of the in 
vitro thymoma cell line, RMA) on cell surface co-stimulatory markers, ability to activate T-
cell proliferation and cytokine secretion. These early GM-CSF-derived DCs have the 
potential to be used in cancer immunotherapy studies. 
 
 
Materials and Methods 
 
Mice 
C57BL/6 and BALB/c mice (aged 6-8 weeks) used throughout this study were purchased 
from the Precinct Animal Centre in Alfred Medical Research and Education Precinct and 
Monash Animal Services (Melbourne, Australia). 
 
Generation of early DCs from GM-CSF-derived cultures 
Bone marrow (BM) cells from femurs and tibias of C57BL/6 mice were collected and 
treated with ACK lysis buffer (155 mM NHCl4, 0.1 mM Na-EDTA, 10 mM KHCO3, pH 7.2) 
to lyse erythrocytes. Cells were washed and cultured for 3 or 4 days at 5 x 105 cells/ml 
with complete media consisting of RPMI 1640, 2 mM L-glutamine (Sigma-Aldrich, St 
Louis, USA), 20 mM HEPES (Sigma-Aldrich), 0.1 mM 2-mercaptoethanol (2-ME) (Sigma-
Aldrich), 100 U/ml penicillin, 100 µg/ml streptomycin (Sigma-Aldrich) and 10 % heat-
inactivated foetal calf serum (FCS; Sigma-Aldrich) at 37oC and 5% CO2. GM-CSF (10 
ng/ml; PeproTech, Rocky Hill, USA) with or without IL-4 (5 ng/ml; PeproTech) was added 
to induce DC generation. Cells were harvested on day 3 or 4 unless otherwise stated by 
gentle re-suspension. 
 
Co-incubation of cancer cells and supernatant with DC cultures 
Cancer cell lines (B16-OVA and RMA) were cultured at 37oC and 5% CO2, and at ~80% 
confluence they were removed from the culture flasks. The harvested cells were 
centrifuged at 300  g, 4oC for 5 min and the supernatant was collected. The remaining cell 
pellet was re-suspended in 10 ml of fresh cold culture media. Cancer cells, at 1.25 x 104 
cells/ml, 2.5 x 104 cells/ml or 5 x 104 cells/ml, were added to 5 x 105 DCs derived from a 
GM-CSF BM culture. Furthermore, to examine the effect of soluble factors of such cancer 
cells, 1 ml of cancer supernatant (SN) was added to 5 x 105 DCs in 1 ml of culture 
medium. One milliliter of fresh culture media was added to wells containing only DCs as 
negative control. Cultures were incubated at 37oC and 5% CO2 for 24 h. 
 
Induction of DC activation with LPS 
DCs (5 x 105 cells) from day 3 or 4 cultures were cultured with or without RMA cells (5 x 
104 cells) or RMA supernatant (1 ml) in 24-well plates in 1 ml of complete media for 24 h. 
LPS (1 μg/ml, derived from Escherichia coli) (0111:B4; Sigma-Aldrich) was added to the 
cultures, which were incubated a further 24 h at 37oC and 5% CO2. LPS was added to 
cultured DCs without cancer cells for a positive control; and wells of DC cultures with no 
LPS acted as a negative control. After 24 h, the plates were spun, supernatants were 
collected, and cells were harvested and stained with fluorescent surface markers (CD11c, 
CD80, CD86, and MHCII) for analysis by flow cytometry. 
 
Flow cytometry and data analysis 
Antibodies were purchased from BD Biosciences (Franklin Lakes, USA) unless otherwise 
stated. Culture cells were harvested and labelled with anti-CD11c V450 (HL3) to identify 
DCs. To study the phenotype and maturation status of DCs, cells were also labelled with 
anti-B7H1 PE (MIH5), biotin-conjugated anti-B7H3 (M3.2D7; eBioscience, San Diego, 
USA), anti-B7H4 Alexa Fluor 488 (297219; R&D Systems, McKinley Place NE, USA), 
anti-CD11b PECy7 (M1/70), biotin-conjugated anti-CD80 (16-10A1), anti-CD86 PE (GL1), 
Gr-1 PerCP Cy5.5 (RB6-8C5) and anti-MHCII APCCy7 (M5/114.15.2) where appropriate. 
Either streptavidin FITC or streptavidin APC was used as secondary antibodies. Dead 
cells were discriminated by staining harvested cells with live/dead Fixable Aqua Dead Cell 
Stain Kit (Invitrogen, Life Technologies, Australia Pty Ltd, Victoria, Australia). T-cells were 
labelled with anti-CD3 FITC (17A2), anti-CD4 PerCP (RM4-5) and anti-CD8α APC (53-
6.7) to scrutinise T-cell purity. Antibodies were prepared in flow cytometry staining buffer 
(PBS containing 2% FCS) and cells were stained for 20 min on ice in the dark. Following 
incubation, cells were washed with staining buffer and centrifuged at 300 g at 4 oC for 5 
min. The supernatant was removed and the cells were re-suspended in 100 µl of PBS 
containing 1% paraformaldehyde. Samples were acquired with LSRII (BD Biosciences) at 
AMREP Flow-Cytometry Core Facility (Melbourne, Victoria, Australia). Data was analysed 
with FlowJo Flow Cytometry Analysis Software (TreeStar Inc, Ashland, USA). 
 
Cytokine detection 
To detect and quantify various cytokines secreted within the culture, early GM-CSF-
derived BM cultures were either left un-stimulated, stimulated with LPS, or co-cultured 
with RMA cells or RMA SN. Supernatant was collected at the end of each experiment and 
analysed by cytometric bead array (CBA) (BD Biosciences), following manufacturer’s 
instructions. Briefly, for CBA inflammation kit, 50 µl of culture supernatant or standard 
cytokine solutions (0-5000 pg/ml) was incubated with 50 µl of cytokine capture beads and 
PE detection reagent for 2 h. For TGF-β flex-set, latent TGF-β in the 100 µl of culture 
supernatant was activated with 20 µl of 1M HCl for 10 min, then neutralised by 20 µl of 
1.2 M NaOH/0.5 M HEPES. Then, 50 µl of neutralized culture supernatant or standard 
TGF-β cytokine solution (0-10 000 pg/ml) was incubated with 50 µl of cytokine capture 
beads and PE detection reagent for 2 h. Samples were acquired with LSRII. Acquisition 
setup involved scattering of beads and fluorescence compensation was standardised with 
cytometric setup beads prior to sample acquisition. Estimated concentrations of cytokines 
were calculated using FCAP Array software (Soft Flow Inc, St. Louis Park, USA).  
 
T-cell purification 
Splenocytes from BALB/c mice were collected and incubated with ACK lysis buffer for 3 
min at room temperature to remove erythrocytes. T-cells from splenocytes were isolated 
based on the manufacturer’s instructions using the MACS Pan-T cells isolation kit 
(Miltenyi Biotec, Bergisch Gladbach, Germany). In brief, remaining cells were washed and 
incubated with a cocktail of biotin-conjugated antibodies against CD11b, CD11c, CD19, 
CD45R (B220), CD49b (DX5), CD105, MHCII, and Ter-119 for 10 min on ice and further 
incubated with anti-biotin magnetic beads for 15 min in the 4 oC. The isolation of 
untouched T cells was achieved by depletion of magnetically labelled cells. A small 
aliquot of the sorted T-cells was labelled with anti-CD3 FITC (17A2), anti-CD4 PerCP 
(RM4-5) and anti-CD8α APC (53-6.7) to scrutinize T-cells purity (purity ≥ 95%). The 
antibodies were prepared in flow cytometry staining buffer (PBS + 2% FCS) and the cells 
were stained for 20 minutes on ice in the dark. The samples were then acquired on the 
LSRII (BD Biosciences) at the AMREP Flow-Cytometry Core Facility. Data were analysed 
using FlowJo Flow Cytometry Analysis Software. 
 
Mixed lymphocyte reaction and T-cell proliferation 
Cells from day 3 or 4 GM-CSF BM cultures from C57BL/6 mice that were either left un-
stimulated, stimulated with LPS, or co-cultured with RMA cells or RMA SN were 
harvested, washed, and sorted for CD11b+ cells where necessary to remove RMA cells 
with BD Influx (BD Biosciences). Then, 3 x 103, 104 or 3 x 104 cells from sorted cultures 
were incubated with 105 allogenic BALB/c T-cells in 150 µl of complete media 
(quadruplicates, 96-well U-bottom plates) for 72 h at 37oC and 5% CO2. Next, 1 µCi 3[H]-
thymidine was added and cultures were incubated for a further 18 h at 37oC and 5% CO2. 
To assess T-cell proliferation, radioactivity was measured in counts per minute (CPM) 
using the TopCount NXT Microplate Scintillation and Luminescence Counter 
(PerkinElmer Inc, Waltham, USA). 
 
Statistical analysis 
The data generated are shown in the mean ± SD. All values are graphed and analysed 
for statistical significance using Prism (GraphPad Software Inc, La Jolla, USA). Statistical 
significance was indicated by P-value < 0.05.  
 
Results 
RMA and RMA SN decreased DC generation in BM cultures but induced differential 
expression of activation markers on GM-CSF derived early DCs 
To test the effect of the murine thymoma cancer cell line RMA on DCs generated from 
GM-CSF-derived bone marrow cultures at day 3 or 4, cells were either left unperturbed, 
or exposed to LPS (1 µg/ml), RMA cells (5 x 104 cells) or supernatant (SN) from RMA 
culture (RMA SN) for 24 h. In response to the exposure to RMA or RMA SN, DC 
generation (% CD11c+ cells) was significantly decreased on day 3 (from 40.38% ± 1.84% 
to 22.96% ± 4.93% when exposed to RMA cells, and to 25.9% ± 5.99% when exposed to 
RMA SN) and day 4 cultures (from 41.58% ± 4.98% to 31.08% ± 2.06% when exposed to 
RMA, and to 34.41% ± 3.23% when exposed to RMA SN) compared with untreated 
cultures (Fig. 1A). In contrast, a trend to an increase of DC numbers in response to LPS 
activation was observed (day 3, 45.13% ± 2.46%; day 4, 47.53% ± 3.92%) (Fig. 1A). The 
cell surface marker expression of CD80 and CD86 to LPS, RMA and RMA SN were 
determined (Fig. 1B). Both LPS and RMA cells significantly increased surface expression 
of CD80 (from 5.38% ± 1.38% to 13.39% ± 0.39% when exposed to LPS, and to 20.18% 
± 2.21% when exposed to RMA) and CD86 (from 20.97% ± 2.86% to 34.3% ± 2.89% 
when exposed to LPS, and to 31.7% ± 5.43% when exposed to RMA) on day 3. 
Surprisingly, RMA SN only increased surface expression of CD80 (23.78% ± 0.73%) but 
not CD86 (17.5% ± 3.06%) on day 3. We further analysed the ratio of CD80:CD86 
expressions within each condition, and noted that RMA (0.64 ± 0.10) and RMA SN (1.38 
± 0.29) significantly increased the ratio on day 3 DCs, in contrast to LPS (0.40 ± 0.03), 
which retained a similar ratio to untreated DCs (0.26 ± 0.09) (Fig. 1C). MHCII expression 
was significantly up-regulated when DCs were exposed to LPS, RMA or RMA SN. 
However, no differences were detected between the three stimulants (data not shown). 
Similar changes in expression of co-stimulatory molecules were noted when stimulating 
GM-CSF cultures on day 4, despite a lower overall expression of the activation markers 
on DCs. Titration studies using a different cancer cell line (B16-OVA) confirmed this result 
(Fig. 2), suggesting that this observation is not restricted only to RMA, and it is effective 
to other cancer cell lines.  
 
RMA and RMA SN prevent T-cell proliferation when incubated with DCs 
To investigate the ability of the early DCs to stimulate T-cell proliferation after exposure to 
LPS, RMA and RMA SN, stimulants were added to the cultures on day 3 and cells were 
incubated for a further 24 h at 37oC and 5% CO2 before they were harvested and sorted 
for CD11b+ cells. Then 3 x 103, 1 x 104 or 3 x 104 sorted cells were incubated with 105 
allogenic BALB/c T-cells (CD3+ cells enriched from the spleen with pan T-cell isolation kit) 
in 150 µl of complete media in 96 well U-bottom plates for a further 3 days at 37oC and 
5% CO2. To measure T-cell proliferation, 1 µCi of 3[H]-thymidine was added and 
incubated for an additional 18 h. Early DCs co-cultured with RMA or RMA SN inhibited T-
cell proliferation (on both day 3 and day 4 of GM-CSF cultures) compared with DC 
cultures without RMA or RMA SN (Fig. 3). Early DCs that were co-cultured with control 
stimulant, LPS, promoted T-cell proliferation. These data indicated that RMA and RMA 
SN altered the activation status of DCs, which prevented these cells from inducing T-cell 
proliferation. 
 
Cytokine secretion in GM-CSF derived bone marrow cultures in the presence of 
RMA 
Cytokine profile from day 3 and day 4 GM-CSF cultures after stimulation with LPS, RMA 
or RMA SN for 24 hours at 37oC and 5% CO2 was determined (Fig. 4). To harvest the 
supernatants, plates were spun at 300 g, 4 oC for 5 min and the supernatants were 
carefully taken off and analysed for the presence of several cytokines and chemokines 
(IL-6, IL-10, IL-12p70, IFN-γ, CCL2, TNF-α, TGF-β) using CBA detection kit (BD 
Biosciences). IL-6 level was increased from 487.23 ± 36.76 pg/ml to 15478.23 ± 2794.99 
pg/ml, IL-10 level was increased from 0 pg/ml to 463.00 ± 7.67 pg/ml, CCL2 level was 
increased from 310.99 ± 21.05 pg/ml to 1058.78 ± 140.66 pg/ml, and TNF-α levels from 
656.81 ± 25.77 pg/ml to 9823.2 ± 180 pg/ml in response to stimulation with LPS (Fig. 4). 
Cells incubated with RMA cells or RMA SN also showed increased cytokine secretion, 
although at much lower levels than those noted with LPS stimulation. It was interesting to 
note that in day 4 GM-CSF cultures, LPS induced higher IL-6 level (from 362.54 ± 160.94 
pg/ml to 28042.37± 2587.13 pg/ml), but lower levels of IL-10 (from 0 pg/ml to 250.91± 
8.77 pg/ml), CCL2 (from 126.69 ± 0.47 pg/ml to 180.47 ± 12.58 pg/ml) and TNF-α (from 
369.19 ± 8.28 pg/ml to 7373.1 ± 219.16 pg/ml) when compared with day 3 cultures. 
However, cells incubated with RMA and RMA SN had no significant alterations in the 
cytokine secretions. In contrast, no significant difference in the amount of TGF-β in the 
culture had been detected in supernatant of day 3 or day 4 GM-CSF cultures regardless 
of the stimulants. No IFN-γ or IL-12p70 was detected in either day 3 or day 4 GM-CSF 
cultures, regardless of the stimulant (data not shown). 
 
Further incubation with LPS did not significantly increase early DC numbers or co-
stimulatory marker expression on DCs that have been pre-exposed to RMA cells or 
RMA SN 
In order to determine whether an additional inflammatory stimulus could reverse the 
RMA-induced effect on early DC cultures by stimulating the cultures that have been 
exposed to RMA cells or RMA SN with LPS (1 µg/ml) for another 24 h at 37oC and 5% 
CO2. We observed a small, but insignificant increase in DC generation in cultures 
stimulated with RMA + LPS when compared to cultures stimulated with RMA only in in 
both day 3 and day 4 cultures (Fig. 5A). The same trend could be seen in day 3 and day 
4 DCs + RMA cultures. Apart from increased DC generation, on day 3, the CD11c+ cells 
also showed elevated expression of CD80 (from DCs + RMA 20.18% ± 2.21% to DCs + 
RMA + LPS 23.63% ± 3%; from DCs + RMA SN 23.78% ± 0.73% to DCs RMA SN + LPS 
26.68% ± 2%). Interestingly, the additional LPS stimulation significantly increased CD86 
expression (from DCs + RMA 31.7% ± 5.43% to DCs + RMA + LPS 48.1% ± 6.38%) (Fig. 
5B). Similar effects were noted in cultures stimulated with RMA cells or RMA SN on day 
4, although the effect was less prominent (Fig. 5B). When the ratio of CD80:CD86 was 
measured, it was clear that LPS decreased the ratio in cultures exposed to RMA cells 
(from 0.65 ± 0.1 to 0.5 ± 0.08) and RMA SN (from 1.38 ± 0.29 to 1.04 ± 0.1) on day 3, 
albeit not significant (Fig. 5C). However, the decrease diminished in day 4 cultures 
exposed to RMA cells and RMA SN. It was also noted that the ratio of CD80:CD86 was 
still significantly higher in both day 3 and day 4 cultures exposed to RMA SN further 
stimulated with LPS (Fig. 5C) when compared with cultures stimulated only with LPS 
(0.40 ± 0.03). There was also upregulation of CD40 expression on day 3 DCs after 
treatment with RMA cells or RMA SN, but not comparable to DCs stimulated with LPS 
(data not shown); no differences were noted in CD40 expression with day 4 DCs 
stimulated with LPS, RMA or non-stimulated (data not shown). 
 
Additional incubation with LPS increased cytokine secretions by GM-CSF-derived 
cells that have been pre-exposed to RMA cells or RMA SN 
Additionally, we examined the SNs of the GM-CSF-derived cells that had been pre-
exposed to RMA cells or RMA SN and stimulated again with LPS (1 µg/ml) for 24 h at 
37oC and 5% CO2 for changes in cytokine secretions compared with cultures without the 
addition of LPS stimulation. We noted a drastic increase of IL-6 from 1316.51± 266.95 
pg/ml to 31983.5± 0.433 pg/ml, IL-10 from 25.25 ± 3.1 pg/ml to 484.69 ± 77.77 pg/ml, 
TNF-α from 1123.26 ± 186.08 pg/ml to 8418.98 ± 576.82 pg/ml and the chemokine CCL2 
from 805.88 ± 161.73 pg/ml to 2647.51 ± 65.06 pg/ml in day 3 GM-CSF derived cell 
cultures that had been pre-exposed to RMA cells after additional LPS stimulation when 
compared to cultures without additional LPS stimulation (Fig. 6). Similar observations 
were made for day 4 GM-CSF derived cells, pre-exposed to RMA cells and stimulated 
with LPS for 24 h, although overall cytokine secretion was lower when compared with day 
3 cultures, except for IL-6. Cultures pre-exposed to RMA SN showed a slightly different 
pattern. While IL-6 secretion in day 3 cultures after LPS stimulation was comparable to 
that in cultures pre-exposed to RMA cells, it was significantly lower in supernatants from 
day 4 GM-CSF-derived cells pre-exposed to RMA SN + LPS (RMA + LPS 13983.5 ± 0.43 
pg/ml; DCs + RMA SN + LPS 3905.43 ± 1280.48 pg/ml). IL-10 levels were increased in 
supernatant from day 3 cultures, though not as much as that seen in the day 4 cultures 
pre-exposed with RMA cells (from DCs + RMA SN 27.45± 14.98 pg/ml to DCs + RMA SN 
+ LPS 42.74 ± 9.42 pg/ml). Interestingly, negligible levels of IL-10 were detected in day 4 
GM-CSF cultures pre-exposed to RMA SN, and further stimulation with LPS did not 
change that. Similarly, a small increase of CCL2 was detected in day 3 cultures pre-
exposed to RMA SN and stimulated with LPS, but no change was seen under the same 
conditions in day 4 GM-CSF-derived cultures. We also tested TGF-β secretion. However, 
further stimulation of day 3 or day 4 GM-CSF-derived cultures pre-exposed to either RMA 
cells or RMA SN with LPS did not yield any detectable differences (data not shown). No 
IFN-γ or IL-12p70 could be detected in the cultures.  
 
 
Discussion 
We have demonstrated that early GM-CSF-derived DCs are highly functional when 
compared to the early GM-CSF + IL-4 DCs (Fig. 7). In addition, we previously 
demonstrated that reactive oxygen species (ROS) induction in GM-CSF-derived DCs 
correlated with inflammatory DC functionality and expansion. Day 4 GM-CSF DC cultures 
expressed very high levels of ROS and day 3 ROS(lo) DCs were highly responsive to toll-
like receptor stimuli (LPS) by rapid upregulation of CD80, CD86, and MHC class II, in 
contrast to the low response of day 6 ROS(hi) DCs [16]. Herein, we further explored the 
effects of the in vitro cancer cell line RMA on early GM-CSF bone marrow-derived DCs. 
We hypothesised that exposure to cancer cell lines such as RMA may activate the early 
GM-CSF-derived DCs, increasing the expression of co-stimulatory molecules, secretion 
of pro-inflammatory cytokines and stimulation of T-cell proliferation. First, we analysed the 
effects on DC (identified as CD11c+ cells) generation and expression of activation 
markers upon exposure to RMA cells and RMA SN. We noted a significant decrease in 
the percentage of DCs within the culture after exposure to RMA cells or RMA SN but not 
after LPS stimulation for both, cultures stimulated on day 3 as well as day 4. This effect 
was also seen when using another cancer cell line, B16-OVA, for stimulation, suggesting 
that the effect is not limited to the RMA cell line. It was interesting that RMA cells appear 
to skew the expression of co-stimulatory markers towards CD86, when in contrast, RMA 
SN induced a higher percentage of cells to express CD80, as is shown in the higher ratio 
of CD80:CD86 expression when compared with RMA cells. CD80 and CD86 are 
important and well-studied activation markers that bind to the T-cell co-stimulatory 
markers CD28 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, CD152) [19-
21]. CTLA-4 is known to act as a strong negative regulator for T-cell activation [22] and 
several studies have shown that CD80 has a higher affinity to binding CTLA-4 than CD86 
[23, 24]. Driving the expression of the co-stimulatory molecules on the DCs towards CD80 
over CD86 will ensure a stronger CTLA-4 response, thus weakening the T-cell response 
to any foreign antigen in the periphery. These results suggest that early DCs that were 
exposed to RMA SN are unable to stimulate T-cell proliferation. 
Indeed, no T-cell proliferation was induced by DCs which had been pre-exposed to 
RMA SN. Interestingly, DCs exposed to RMA cells before incubation with T-cells were not 
able to induce T-cell proliferation either, which suggests additional mechanisms are being 
engaged by the cancer cell line. It has been demonstrated in many studies that DCs can 
express inhibitory markers to regulate T-cell function [25-28]. Earlier results from our lab 
showed that GM-CSF-derived DCs express moderate levels of inhibitory marker, 
programmed death ligand 1 (PD-L1 or B7H1) but not B7H3 and B7H4 in their resting 
state (Fig. 8). While it has not been tested if RMA cells or RMA SN increase any of the 
inhibitory marker expression, these GM-CSF-derived early DCs induce robust T-cell 
proliferation after LPS stimulation in spite of the pre-existing PD-L1 expression, 
suggesting that these DCs can induce a strong immune response when given a proper 
stimulation. This was in line with a study done by Bhattacharya et al. [29] where they 
demonstrated that BM-derived DCs selectively expand regulatory T-cells in the presence 
of OX40L but not PD-L1. Furthermore, blockade of CD80 on BM-derived DCs has also 
been shown to discourage regulatory T-cell expansion. The lack of T-cell proliferation was 
not only triggered by the binding to co-stimulatory markers expressed on DCs, but also 
triggered by cytokines found in the immediate cellular environment. IL-6 has been shown 
to trigger a strong T-cell response [30]. IL-6 acts as both a pro-inflammatory and an anti-
inflammatory cytokine. In cancer patients, IL-6 is highly elevated, leading to poor 
prognosis [31], and is abundant at the tumour microenvironment where it plays a role in 
cancer metastasis via down-regulation of E-cadherin [32]. In mice, CT-26 colorectal 
cancer cells expressing IL-6 exert tumour-promoting activities by activating growth and 
survival [33]. TNF-α, a pro-inflammatory cytokine, is involved in pathological process of 
chronic inflammation, autoimmune diseases and cancer growth [34]. Furthermore, the 
combination of pro-inflammatory cytokines, TNF-α and IL-6, has been shown to 
synergistically induce strong signal for T-cell proliferation [35] and cancer cell growth [36]. 
We demonstrated that LPS induced expression of co-stimulatory markers and high levels 
of cytokine secretion, both of which can provide strong signals to promote T-cell 
proliferation. On the other hand, RMA cells and RMA SN did induce much lower levels of 
cytokine secretion and differential expression of co-stimulatory markers on DCs. The 
cytokine profile together with the altered CD80 and CD86 expression may contribute to 
the absence of T-cell proliferation by the early DCs that have been pre-exposed to RMA 
cells or RMA SN. In addition, further studies need to be conducted to measure the effects 
of RMA and RMA SN on the expression of B7H1 on these DCs. 
In an attempt to reverse the negative effects from the exposure of the DCs to the 
cancer cells or SN, GM-CSF DC cultures that had been co-incubated with RMA cells or 
RMA SN were stimulated with LPS. The additional stimulation with LPS increased 
cytokine secretion in the cultures pre-exposed to RMA cells and RMA SN compared with 
the same cultures without additional LPS stimulation. Also, generation of DCs in the GM-
CSF-derived cultures could be rescued to a small extent by addition of LPS post 
exposure to RMA cells or RMA SN. We furthermore observed a trend in LPS-stimulated 
cultures that showed a reduction of the ratio of CD80:CD86 expression. However, these 
changes were not significant. Although we did not achieve significance in our 
experiments, the results are in line with studies that reported positive therapeutic effects 
from administering LPS or synthetic lipid A molecule into animal cancer models [37, 38]. 
The inhibition of tumour growth was associated with a dose-dependent effect, and 
animals received antigenic memory from LPS-eradicated tumours [39, 40]. These results 
are promising, but more research is required to determine the ideal dose of LPS to obtain 
a tumouricidal effect while, at the same time, avoiding the toxic side effects of LPS.  
Human DCs, particularly the classic myeloid DCs, express activation markers such 
as CD80, CD86 and HLA-DR (equivalent to MHCII), which is similar to mice [41]. Due to 
the similarities in activation pathway in these DCs, we speculate that human cancer cell 
lines may interact with culture DCs in similar ways. However, one major difference 
between human and mice DCs is the differential expression of TLRs. For example, 
human DCs only express low levels of TLR4 when compared with their mouse 
counterparts [42, 43]. While lower TLR4 expression corresponds to a weaker response to 
LPS [44], a higher dose of LPS can still initiate DC activation [45]. The differences in TLR 
expressions may also affect DCs’ response against cancer cells. Therefore, there is still 
much testing to be conducted to test the possible use of this DC model in future cancer 
immunotherapies. 
In summary, we show that RMA cells and RMA SN can induce differential co-
stimulatory marker expressions and cytokine secretion in early DCs derived from GM-
CSF cultures and that further stimulation with LPS can not fully reverse the suppressive 
effect of cancer cells or supernatant. Although these early DCs were previously shown to 
be potent activators of T-cell stimulation, this is inhibited in the presence of cancer, and 
further studies are required to determine the function and use of GM-CSF-derived DCs 
and their ability to be used in cancer immunotherapy studies. 
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Figure Legends 
 
Figure 1. RMA and RMA SN decrease DC generation in bone marrow cultures but 
induce differential expression of activation markers on these GM-CSF derived DCs  
Day 3 and day 4 DCs generated from GM-CSF bone marrow cultures either not 
stimulated (NS; black), stimulated with LPS (dark grey), RMA (5 x 104 cells/ml) (light grey) 
or RMA SN (white) for 24 h. (A) The percentage of DCs (CD11c+ cells) generated and (B) 
surface expression of CD80 and CD86 on DCs were determined by flow cytometry. (C) 
Ratios of CD80:CD86 expression on early DCs were calculated. Results shown are the 
average of 3 mice, Two-way ANOVA was used used to calculate statistical significance. 
Results are shown as the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001. 
 Figure 2. Cancer cell lines decrease DC generation in bone marrow cultures and 
increase expression of co-stimulatory markers  Day 3 and day 4 DCs generated from 
GM-CSF bone marrow cultures either not stimulated (NS; black), stimulated with B16-
OVA at 2.5 x 104 cells/ml (dark grey), 5 x 104 cells/ml (light grey) or 105 cells/ml (white) for 
24 h. (A) Percentage of DCs (CD11c+ cells) generated; and (B) the expression of co-
stimulatory markers (CD80, CD86) was measured by flow cytometry. Results shown are 
the average of 3 mice, two-way ANOVA was used used to calculate statistical 
significance. Results are shown as the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001. 
 
Figure 3. DCs pre-exposed to RMA cells and RMA SN can not induce T-cell 
proliferation  T-cells were incubated with day 3 or day 4 DCs which were either not 
stimulated (black), stimulated with LPS (dark grey), stimulated with RMA (light grey) or 
stimulated with RMA SN (white) for 24 hours beforehand. Culture cells were harvested 
and incubated with T-cells at ratios of 1:30, 1:10 and 1:3 for 3 days. Proliferation of T-cells 
was measured by 3[H]-thymidine incorporation. Results shown are the average of 3 mice. 
Two-way ANOVA was used used to calculate statistical significance. Results are shown 
as the mean ± SD. ** P < 0.01, *** P< 0.001. 
 
Figure 4. Cytokine and chemokine secretion in GM-CSF-derived bone marrow 
cultures in the presence of RMA  Culture supernatant from the day 3 and day 4 cultures 
either not stimulated or stimulated with LPS, RMA or RMA supernatant (RMA SN) was 
harvested and cytokines (IL-6, IL-10, CCL2, TNF-α and TGF-β) secreted within the 
culture were analysed using a cytometric bead array (CBA). Results shown are the 
average of 3 mice. Two-way ANOVA was used used to calculate statistical significance. 
Results are shown as the mean ± SD. * P < 0.05, ** P < 0.01, ***P < 0.001. 
 
Figure 5. Additional incubation with LPS does not rescue early DC generation from 
GM-CSF cultures pre-exposed to RMA cells or RMA SN or change expression of co-
stimulatory markers  Day 3 or day 4 cultures were either left unstimulated (NS), 
stimulated with RMA cells or SN for 24 hours before being further stimulated with LPS for 
24 hours, at 37C, 5% CO2. Cultures were harvested and (A) percentage of DCs (CD11c+ 
cells) and (B) expression of co-stimulatory markers (CD80 and CD86) on these DCs were 
analysed by flow cytometry. (C) Ratios of CD80:CD86 expression on early DCs were 
calculated by dividing the percentage of CD80 with percentage of CD86. Results shown 
are the average of 3 mice. Two-way ANOVA was used used to calculate statistical 
significance. Each condition was compared with NS condition (black) unless stated 
otherwise. Results are shown as the mean ± SD. * P < 0.05; ** P < 0.01, *** P < 0.001. 
 
Figure 6. Further incubation with LPS increases cytokines and chemokine 
secretion within the culture   (A) Day 3 or day 4 cultures were stimulated with RMA 
cells or SN for 24 hours before being further stimulated with LPS for 24 hours at 37C, 5% 
CO2 both times. Culture supernatants from each culture conditions were collected and 
cytokine secretion was analysed with cytometric bead array (CBA). (B) Ratios of CD80 
expression: cytokine secretion by early DCs were calculated by dividing the percentage of 
CD80 expression with the amount of cytokine secreted in pg/ml. The same calculation 
was done for the ratios of CD86 expression:cytokine secretion by early DCs. Results 
shown are the average of 3 mice. Two-way ANOVA was used used to calculate statistical 
significance. Results are shown as the mean ± SD. * P < 0.05; ** P < 0.01, *** P < 0.001. 
 
Figure 7. Comparison between GM-CSF and GM-CSF + IL-4-derived DCs   (A) The 
endocytosis of bone marrow-derived DCs were analysed by incubating the cells with 40 
nm or 500 nm nanoparticles for 1 hour before these cells were harvested and analysed 
using flow cytometry. (B) Bone marrow derived DCs were cultured for 3 to 5 days before 
they were stimulated with LPS for 24 hours; NS depicts non-stimulated. The expression 
levels of activation markers, CD80, CD86 and MHCII were measured using flow 
cytometry. Each histogram shown represents 3 different experiments, bar graphs were 
results from 3 mice. Two-way ANOVA was used to compare both experimental conditions 
at each time-point. (C) Supernatants from bone marrow-derived GM-CSF DC and GM-
CSF+IL-4 DC cultures generated on day 3, day 4 and day 5 were collected and cytokines 
were measured with cytometric bead array (CBA). Bar graphs were results from 2 mice. 
Results are shown as the the mean ± SD. * P < 0.05; ** P < 0.01, *** P < 0.001. 
 
Figure 8. Expression of co-inhibitory molecules on GM-CSF derived early DCs  Day 
3 DCs were generated from GM-CSF bone marrow cultures and the expression of B7H1 
(PD-L1), B7H3 and B7H4 were analysed using flow cytometry. Each dot plot is 
representative of 3 different mice. 
 
